BD to Offer Drug Candidate ADME Screening with BioTrove System | GenomeWeb
NEW YORK (GenomeWeb News) – BioTrove said today that Becton Dickinson will offer BioTrove’s mass spectrometry-based screening and analysis system as part of its ADME analysis services for pharmaceutical and biotech companies
 
Under the agreement, BD will offer BioTrove’s mass spec-based RapidFire Technology as part of its drug absorption, distribution, metabolism, and elimination services offering.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.